Blood Biomarkers for Alzheimer’s Dementia Diagnosis
Alzheimer’s disease (AD) represents a major public health concern and has been identified as a research priority. Clinical research evidence supports that the core cerebrospinal fluid (CSF) biomarkers for AD, including amyloid-β (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau), reflect key...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society for Clinical Laboratory Science
2022-12-01
|
| Series: | Korean Journal of Clinical Laboratory Science |
| Subjects: | |
| Online Access: | http://www.kjcls.org/journal/view.html?doi=10.15324/kjcls.2022.54.4.249 |
| _version_ | 1797960171169775616 |
|---|---|
| author | Chang-Eun Park |
| author_facet | Chang-Eun Park |
| author_sort | Chang-Eun Park |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) represents a major public health concern and has been identified as a research priority. Clinical research evidence supports that the core cerebrospinal fluid (CSF) biomarkers for AD, including amyloid-β (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau), reflect key elements of AD pathophysiology. Nevertheless, advances in the clinical identification of new indicators will be critical not only for the discovery of sensitive, specific, and reliable biomarkers of preclinical AD pathology, but also for the development of tests that facilitate the early detection and differential diagnosis of dementia and disease progression monitoring. The early detection of AD in its presymptomatic stages would represent a great opportunity for earlier therapeutic intervention. The chance of successful treatment would be increased since interventions would be performed before extensive synaptic damage and neuronal loss would have occurred. In this study, the importance of developing an early diagnostic method using cognitive decline biomarkers that can discriminate between normal, mild cognitive impairment (MCI), and AD preclinical stages has been emphasized. |
| first_indexed | 2024-04-11T00:42:07Z |
| format | Article |
| id | doaj.art-0c282e42b3ce40568b828cc65a6d8133 |
| institution | Directory Open Access Journal |
| issn | 1738-3544 |
| language | English |
| last_indexed | 2024-04-11T00:42:07Z |
| publishDate | 2022-12-01 |
| publisher | The Korean Society for Clinical Laboratory Science |
| record_format | Article |
| series | Korean Journal of Clinical Laboratory Science |
| spelling | doaj.art-0c282e42b3ce40568b828cc65a6d81332023-01-06T01:44:16ZengThe Korean Society for Clinical Laboratory ScienceKorean Journal of Clinical Laboratory Science1738-35442022-12-0154424925510.15324/kjcls.2022.54.4.249kjcls.2022.54.4.249Blood Biomarkers for Alzheimer’s Dementia DiagnosisChang-Eun Park0Department of Biomedical Laboratory Science, Molecular Diagnostics Research Institute, Namseoul University, Cheonan, KoreaAlzheimer’s disease (AD) represents a major public health concern and has been identified as a research priority. Clinical research evidence supports that the core cerebrospinal fluid (CSF) biomarkers for AD, including amyloid-β (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau), reflect key elements of AD pathophysiology. Nevertheless, advances in the clinical identification of new indicators will be critical not only for the discovery of sensitive, specific, and reliable biomarkers of preclinical AD pathology, but also for the development of tests that facilitate the early detection and differential diagnosis of dementia and disease progression monitoring. The early detection of AD in its presymptomatic stages would represent a great opportunity for earlier therapeutic intervention. The chance of successful treatment would be increased since interventions would be performed before extensive synaptic damage and neuronal loss would have occurred. In this study, the importance of developing an early diagnostic method using cognitive decline biomarkers that can discriminate between normal, mild cognitive impairment (MCI), and AD preclinical stages has been emphasized.http://www.kjcls.org/journal/view.html?doi=10.15324/kjcls.2022.54.4.249alzheimer diseasebiomarkerdementiaearly diagnosislaboratory detection |
| spellingShingle | Chang-Eun Park Blood Biomarkers for Alzheimer’s Dementia Diagnosis Korean Journal of Clinical Laboratory Science alzheimer disease biomarker dementia early diagnosis laboratory detection |
| title | Blood Biomarkers for Alzheimer’s Dementia Diagnosis |
| title_full | Blood Biomarkers for Alzheimer’s Dementia Diagnosis |
| title_fullStr | Blood Biomarkers for Alzheimer’s Dementia Diagnosis |
| title_full_unstemmed | Blood Biomarkers for Alzheimer’s Dementia Diagnosis |
| title_short | Blood Biomarkers for Alzheimer’s Dementia Diagnosis |
| title_sort | blood biomarkers for alzheimer s dementia diagnosis |
| topic | alzheimer disease biomarker dementia early diagnosis laboratory detection |
| url | http://www.kjcls.org/journal/view.html?doi=10.15324/kjcls.2022.54.4.249 |
| work_keys_str_mv | AT changeunpark bloodbiomarkersforalzheimersdementiadiagnosis |